Clinical trials group Icon has acquired research organisation ClinicalRM in a move designed to improve its ability to access government-sponsored research.

The acquisition will also see Icon build up its business in vaccines and infectious disease, where ClinicalRM specialises.

ClinicalRM also works with US government agencies and commercial customers to respond to the threat of global viral epidemics.

Icon chief executive Ciarán Murray said the market for government-sponsored research was “significant” with more than 1,500 active clinical studies being funded by the National Institutes of Health or other federal agencies.

“ClinicalRM has strong relationships and a deep understanding of what is required to partner successfully with government sponsors,” he said. “They will provide Icon a platform to further penetrate this market segment as part of our strategy to grow and diversify our customer base.

“ClinicalRM’s experience in responding to the challenges of global viruses will further enhance Icon’s capabilities in the areas of vaccines and infectious disease, benefiting our customers and patients globally.”

ClinicalRM chief executive Victoria Tifft said the move would lead to “additional services and thought leadership” for the group’s customers. No price was disclosed.